These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37122097)

  • 41. Early Alzheimer-type lesions in cognitively normal subjects.
    Tsartsalis S; Xekardaki A; Hof PR; Kövari E; Bouras C
    Neurobiol Aging; 2018 Feb; 62():34-44. PubMed ID: 29107845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy.
    Chen X; Firulyova M; Manis M; Herz J; Smirnov I; Aladyeva E; Wang C; Bao X; Finn MB; Hu H; Shchukina I; Kim MW; Yuede CM; Kipnis J; Artyomov MN; Ulrich JD; Holtzman DM
    Nature; 2023 Mar; 615(7953):668-677. PubMed ID: 36890231
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased acetylation of microtubules rescues human tau-induced microtubule defects and neuromuscular junction abnormalities in
    Mao CX; Wen X; Jin S; Zhang YQ
    Dis Model Mech; 2017 Oct; 10(10):1245-1252. PubMed ID: 28819043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Break and accelerator-The mechanics of Tau (and amyloid) toxicity.
    Cruz E; Nisbet RM; Götz J
    Cytoskeleton (Hoboken); 2024 Jan; 81(1):24-29. PubMed ID: 37632370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Role of Tau Proteoforms in Health and Disease.
    Waheed Z; Choudhary J; Jatala FH; Fatimah ; Noor A; Zerr I; Zafar S
    Mol Neurobiol; 2023 Sep; 60(9):5155-5166. PubMed ID: 37266762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of tau self-aggregation and neurotoxicity.
    Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A three-dimensional human neural cell culture model of Alzheimer's disease.
    Choi SH; Kim YH; Hebisch M; Sliwinski C; Lee S; D'Avanzo C; Chen H; Hooli B; Asselin C; Muffat J; Klee JB; Zhang C; Wainger BJ; Peitz M; Kovacs DM; Woolf CJ; Wagner SL; Tanzi RE; Kim DY
    Nature; 2014 Nov; 515(7526):274-8. PubMed ID: 25307057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TBK1 interacts with tau and enhances neurodegeneration in tauopathy.
    Abreha MH; Ojelade S; Dammer EB; McEachin ZT; Duong DM; Gearing M; Bassell GJ; Lah JJ; Levey AI; Shulman JM; Seyfried NT
    J Biol Chem; 2021; 296():100760. PubMed ID: 33965374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.
    Brunden KR; Zhang B; Carroll J; Yao Y; Potuzak JS; Hogan AM; Iba M; James MJ; Xie SX; Ballatore C; Smith AB; Lee VM; Trojanowski JQ
    J Neurosci; 2010 Oct; 30(41):13861-6. PubMed ID: 20943926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity.
    Alonso Adel C; Li B; Grundke-Iqbal I; Iqbal K
    Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8864-9. PubMed ID: 16735465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anesthesia promotes acute expression of genes related to Alzheimer's disease and latent tau aggregation in transgenic mouse models of tauopathy.
    Eun JD; Jimenez H; Adrien L; Wolin A; Marambaud P; Davies P; Koppel JL
    Mol Med; 2022 Jul; 28(1):83. PubMed ID: 35858831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo.
    Cowan CM; Bossing T; Page A; Shepherd D; Mudher A
    Acta Neuropathol; 2010 Nov; 120(5):593-604. PubMed ID: 20617325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dephosphorylation Targeting Chimaera (DEPTAC): Targeting Tau Proteins in Tauopathies.
    Soumbasis A; Eldeeb MA; Ragheb MA; Zorca CE
    Curr Protein Pept Sci; 2022; 23(3):129-132. PubMed ID: 35598241
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tau immunotherapy in Alzheimer's disease and progressive supranuclear palsy.
    Karimi N; Bayram Çatak F; Arslan E; Saghazadeh A; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109445. PubMed ID: 36410182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A rapid gene delivery-based mouse model for early-stage Alzheimer disease-type tauopathy.
    Siman R; Lin YG; Malthankar-Phatak G; Dong Y
    J Neuropathol Exp Neurol; 2013 Nov; 72(11):1062-71. PubMed ID: 24128676
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Untangling the Tauopathy for Alzheimer's disease and parkinsonism.
    Chang HY; Sang TK; Chiang AS
    J Biomed Sci; 2018 Jul; 25(1):54. PubMed ID: 29991349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Amyloidogenesis of Tau protein.
    Nizynski B; Dzwolak W; Nieznanski K
    Protein Sci; 2017 Nov; 26(11):2126-2150. PubMed ID: 28833749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimer's Disease and Primary Tauopathy Postmortem Brains.
    Helboe L; Rosenqvist N; Volbracht C; Pedersen LØ; Pedersen JT; Christensen S; Egebjerg J; Christoffersen CT; Bang-Andersen B; Beach TG; Serrano GE; Falsig J
    J Alzheimers Dis; 2022; 88(1):207-228. PubMed ID: 35570492
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
    Badiola N; Suárez-Calvet M; Lleó A
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.